Skip to content
OpenCapital
Get started

Lantheus Holdings LNTH PYLARIFY — Revenue

Other product segments

Oncology
$240.92M—
Cardiology
$84.63M—
Definity
$84.63M+6.8%
Neuraceq
$35.44M—
Neurology
$35.44M—
Strategic Partnerships And Other
$16.34M+52.1%
Licenseand Royalty Revenues
$7.48M+28.0%
SPECT Business
$0—

Similar metrics at other companies

LQD
LQDAProduct — Revenue
$129.88M—
PTC Therapeutics logo
PTCTProduct — Revenue
$225.57M+47.0%
Mobileye Global Inc. logo
MBLYPL — Revenue
$28M0.0%
Axsome Therapeutics logo
AXSMProduct — Revenue
$189.4M+57.4%
Alkermes logo
ALKSProduct — Revenue
$338.11M+38.3%
Ionis Pharmaceuticals logo
IONSProduct — Revenue
$42.96M+583%

Other financials

Income statement

See full
Revenue$377.3M+1.2%
Gross profit$230.9M-2.9%
Operating income$81.3M-20.3%
Net income$118.4M+62.3%
EPS (diluted)$1.80+76.5%

Balance sheet

See full
Cash & equivalents$500.3M-46.8%
Total debt$627.9M+1.8%
Total equity$1.2B+4.1%
Total assets$2.3B+14.2%

Cash flow

See full
Operating cash flow$125.1M+16.3%
CapEx$3.2M-63.0%
Free cash flow$121.9M+23.3%

Valuation

See full
Market cap$6.76B-26.3%
Enterprise value$6.89B-20.5%
P/E24.2×-10.2×
P/S4.4×-1.6×

Profitability

See full
Gross margin60.5%-3.6pp
Operating margin18.8%-10.7pp
Net margin18%+0.7pp
FCF margin24.4%-6.4pp

Returns & leverage

See full
Return on equity23.5%-1.7pp
Debt / equity0.5×0.0×
Current ratio2.8×-2.9×

Where this comes from

Reported directly by Lantheus Holdings in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The official record: Lantheus Holdings’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Lantheus Holdings's pylarify — revenue.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Lantheus Holdings's PYLARIFY — revenue?
Lantheus Holdings (LNTH) reported PYLARIFY — revenue of $240.92M in Q1 2026.
How has Lantheus Holdings's PYLARIFY — revenue changed year-over-year?
Lantheus Holdings's PYLARIFY — revenue decreased by 6.5% year-over-year, from $257.65M to $240.92M.
What is the long-term trend for Lantheus Holdings's PYLARIFY — revenue?
Over 4 years (2021 to 2025), Lantheus Holdings's PYLARIFY — revenue has grown at a 118.5% compound annual growth rate (CAGR), from $43.41M to $989.12M.
What does PYLARIFY — revenue mean?
This metric represents the total gross revenue generated from the sale of a specific diagnostic product line, excluding any taxes collected from customers. It serves as a primary indicator of market adoption and commercial performance for the company's key therapeutic or diagnostic offerings. Tracking this revenue stream allows investors to evaluate the growth trajectory and demand for specific product portfolios within the broader healthcare segment.